PELyon (Pharmaco Epidemiology Lyon), Lyon, France.
PELyon (Pharmaco Epidemiology Lyon), Lyon, France.
Vaccine. 2021 Jan 15;39(3):505-511. doi: 10.1016/j.vaccine.2020.12.021. Epub 2020 Dec 21.
Maintaining a high vaccination coverage rate (VCR) throughout the lifetime and complying with the National Immunization Program are essential to optimize the protection of the population. The study objectives were to evaluate the evolution of the VCRs and the compliance with the vaccination visits for the diphtheria, tetanus, poliomyelitis and pertussis boosters in France since the changes implemented in the 2013 National Immunization Program.
Cumulative booster VCRs were estimated at all vaccination visits, from 2013 to 2017, among persons eligible for a booster vaccination from a 1/97th random sample of French claims data. Broader age groups around the recommended ages by the vaccination schedule (6, 11-13, 25, 45, 65, 75, 85, 95y) were used: all persons aged 5 to 8, 10 to 15, 21 to 29, 41 to 49, 61 to 69, 71 to 79, 81 to 89 and 91 to 99.
Over the study period, the diphtheria-tetanus-poliomyelitis booster VCRs increased, reaching in 2017: 73.3% at 8 years old, 75.6% at 15 years old, 46.6% at 29 years old, 38.4% at 49 years old, 36.3% at 69 years old, 30.8% at 79 years old, 22.1% at 89 years old and 11.0% at 99 years old. The pertussis VCRs were also increasing at all vaccination visits, in particular at the vaccination visits at 6 and 11-13 years old (from 16.4% to 63.8% and from 50.3% to 61.2%, respectively). Delayed vaccinations were observed at all vaccination visits.
VCRs for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination increased from 2013 to 2017 while remaining suboptimal across all ages and lower in the adult populations. The analysis also shows that the introduction in 2013 of a pertussis vaccination at 6 years of age was relatively well-established in 2017 while other changes in recommendations were slowly or partially implemented.
在整个生命周期中保持高疫苗接种覆盖率（VCR）并遵守国家免疫计划对于优化人群保护至关重要。本研究的目的是评估自 2013 年国家免疫计划实施以来，法国白喉、破伤风、脊髓灰质炎和百日咳加强针的 VCR 变化和接种情况。
从 2013 年到 2017 年，从法国索赔数据的 1/97 随机样本中，对符合加强针接种条件的人群，在所有加强针接种访问中估算累积加强针 VCR。使用更广泛的年龄组，围绕接种时间表的建议年龄（6、11-13、25、45、65、75、85、95 岁）：所有 5 至 8、10 至 15、21 至 29、41 至 49、61 至 69、71 至 79、81 至 89 和 91 至 99 岁的人。
在研究期间，白喉-破伤风-脊髓灰质炎加强针 VCR 增加，到 2017 年达到：8 岁时 73.3%，15 岁时 75.6%，29 岁时 46.6%，49 岁时 38.4%，69 岁时 36.3%，79 岁时 30.8%，89 岁时 22.1%，99 岁时 11.0%。所有接种访问中百日咳 VCR 也在增加，特别是在 6 岁和 11-13 岁接种访问中（分别从 16.4%增加到 63.8%和从 50.3%增加到 61.2%）。所有接种访问中均观察到延迟接种。
2013 年至 2017 年期间，白喉、破伤风、脊髓灰质炎和百日咳加强针的 VCR 有所增加，但所有年龄段的 VCR 仍不理想，成人人群中的 VCR 更低。分析还表明，2013 年在 6 岁时引入百日咳疫苗接种在 2017 年相对稳定，而建议中的其他变化则缓慢或部分实施。
